Multimodal lipid-lowering treatment in pediatric patients with homozygous familial hypercholesterolemia—target attainment requires further increase of intensity

Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol

(2017) Gilbert R Thompson et al.   EUROPEAN HEART JOURNAL

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

(2017) Marc S. Sabatine et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study

(2017) Frederick J Raal et al.   Lancet Diabetes & Endocrinology

Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular DiseaseHighlights

(2016) Eberhard Roeseler et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom

(2016) Michael France et al.   ATHEROSCLEROSIS

Phenotype diversity among patients with homozygous familial hypercholesterolemia: A cohort study

(2016) Frederick J. Raal et al.   ATHEROSCLEROSIS

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias

(2016) Alberico L. Catapano et al.   EUROPEAN HEART JOURNAL

Disease control via intensified lipoprotein apheresis in three siblings with familial hypercholesterolemia

(2016) Christina Taylan et al.   Journal of Clinical Lipidology

Management of homozygous familial hypercholesterolemia in real-world clinical practice: A report of 7 Italian patients treated in Rome with lomitapide and lipoprotein apheresis

(2016) Claudia Stefanutti et al.   Journal of Clinical Lipidology

Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology

(2016) Børge G. Nordestgaard et al.   JOURNAL OF LIPID RESEARCH

Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease

(2016) Amit V. Khera et al.   NEW ENGLAND JOURNAL OF MEDICINE

Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel

(2016) Raul D Santos et al.   Lancet Diabetes & Endocrinology

TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients – A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose

(2015) U. Schatz et al.   ATHEROSCLEROSIS SUPPLEMENTS

Efficacy, safety, and tolerability of long-term lipoprotein apheresis in patients with LDL- or Lp(a) hyperlipoproteinemia: Findings gathered from more than 36,000 treatments at one center in Germany

(2015) Franz Heigl et al.   ATHEROSCLEROSIS SUPPLEMENTS

Prevalence, Vascular Distribution, and Multiterritorial Extent of Subclinical Atherosclerosis in a Middle-Aged Cohort: The PESA (Progression of Early Subclinical Atherosclerosis) Study

(2015) L. Fernandez-Friera et al.   CIRCULATION

The Agenda for Familial Hypercholesterolemia

(2015) Samuel S. Gidding et al.   CIRCULATION

Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment

(2015) Albert Wiegman et al.   EUROPEAN HEART JOURNAL

Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial

(2015) Frederick J Raal et al.   LANCET

Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials

(2015)   LANCET

Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

(2015) Jennifer G. Robinson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events

(2015) Marc S. Sabatine et al.   NEW ENGLAND JOURNAL OF MEDICINE

Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype–phenotype relationship, and clinical outcome

(2014) Barbara Sjouke et al.   EUROPEAN HEART JOURNAL

Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society

(2014) M. Cuchel et al.   EUROPEAN HEART JOURNAL

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society

(2013) B. G. Nordestgaard et al.   EUROPEAN HEART JOURNAL

Apheresis in homozygous familial hypercholesterolemia: The results of a follow-up of all Norwegian patients with homozygous familial hypercholesterolemia

(2012) Asgeir Græsdal et al.   Journal of Clinical Lipidology

Reduction in Mortality in Subjects With Homozygous Familial Hypercholesterolemia Associated With Advances in Lipid-Lowering Therapy

(2011) Frederick J. Raal et al.   CIRCULATION

Sudden Death in a 4-Year-Old Boy: A Near-Complete Occlusion of the Coronary Artery Caused by an Aggressive Low-Density Lipoprotein Receptor Mutation (W556R) in Homozygous Familial Hypercholesterolemia

(2010) Kurt Widhalm et al.   JOURNAL OF PEDIATRICS

Efficacy criteria and cholesterol targets for LDL apheresis

(2009) Gilbert R. Thompson et al.   ATHEROSCLEROSIS

Long-Term Safety and Efficacy of Low-Density Lipoprotein Apheresis in Childhood for Homozygous Familial Hypercholesterolemia

(2008) Lisa C. Hudgins et al.   AMERICAN JOURNAL OF CARDIOLOGY

Update and Analysis of the University College London Low Density Lipoprotein Receptor Familial Hypercholesterolemia Database

(2008) S. E. A. Leigh et al.   ANNALS OF HUMAN GENETICS

Low-density Lipoprotein Apheresis in Children With Familial Hypercholesterolemia: Follow-up to 21 Years

(2008) Jean-Bernard Palcoux et al.   THERAPEUTIC APHERESIS AND DIALYSIS